ResearcherMount Sinai Medical CenterActive in the last 2 years
Mike Cusnir
Matched on ORCID iD 0000-0002-5983-980X; OpenAlex author ID A5056135111. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers
Papers 5
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
- Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
- Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Ca… Last author DOI 10.3390/diseases10040115↗
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Andrew H. Ko · 1 shared paper, 2025 · strength 0.22
- Eric Andrew Collisson · 1 shared paper, 2025 · strength 0.22
- Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.22
- Raymond Couric Wadlow · 1 shared paper, 2025 · strength 0.22
- Rafael Winograd · 1 shared paper, 2025 · strength 0.22
- Erica S. Tsang · 1 shared paper, 2025 · strength 0.22
- Gregory P. Botta · 1 shared paper, 2025 · strength 0.22
- Kenneth P. Olive · 1 shared paper, 2025 · strength 0.22
- Abed Alhalim Aljamal · 1 shared paper, 2022 · strength 0.19
- Deirdre Jill Cohen · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Bert H. O’Neil · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Antonio Jimeno · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Olugbenga Olanrele Olowokure · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Jordan D. Berlin · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Aaron James Scott · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Steven J. Cohen · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Wells A. Messersmith · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Autumn J. McRee · 2 shared papers, 2015 · strength 0.07
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv264↗
- Paper A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine al… DOI 10.1093/annonc/mdv477↗
- Lawrence Leichman · 1 shared paper, 2015 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.